Recent Updates
Recently added Catalysts
BDX Positive Sentiment Score: 85/100

BD Names Dr. Ronald Silverman as Chief Medical Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS,...

Key Takeaway: BD (Becton, Dickinson and Company) has appointed Dr. Ronald Silverman as the new Chief Medical Officer, effective December 4, 2023. Dr. Silverman, with nearly three decades of experience in medical affairs, replaces Dr. William Sigmund, who is retiring. He will lead the Medical Affairs organization, focusing on improving BD's innovative solutions. Known for his work at 3M Health Care and academic positions at prominent universities, Silverman aims to enhance patient outcomes through effective and personalized healthcare solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ron Silverman brings nearly 30 years of experience in medical affairs and clinical practice.
  • His expertise is expected to advance BD’s innovation pipeline and improve patient outcomes.
  • Silverman has a proven track record with patents and numerous publications.
  • He will contribute to both medical safety and compliance of BD's product portfolio.

Full Press Release Details

FRANKLIN LAKES, N.J. , Nov. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that Ronald (Ron) Silverman , MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023 .
Dr. Silverman will be responsible for leading the company's Medical Affairs organization, which includes end-to-end medical affairs across BD's business units, regions and central team. In this role, he will use medical insights and expertise to advance BD's pipeline of clinically relevant, innovative solutions that align with evolving patient needs, while also contributing to the safety and compliance of BD's in-market portfolio of products. Dr. Silverman will report to Beth McCombs , executive vice president and chief technology officer for BD, and serve as a member of the BD Executive Leadership Team.
"Ron has been dedicated to advancing care for nearly 30 years, working across clinical practice, academic research and industry roles," McCombs said. "Ron's broad expertise and passion for innovation, evidence generation, clinical development, real-world evidence, medical safety, and compliance will help BD build upon our exciting innovation pipeline and promote better outcomes for patients and providers by enabling increasingly efficient, effective and personalized care."
Dr. Silverman replaces Dr. William Sigmund , who has been chief medical officer for BD since January 2018 and announced his intent to retire from the company in June 2023 . Dr. Silverman joins BD from 3M Health Care, where he most recently served as senior vice president and chief medical officer since 2021. He previously led Medical and Clinical Affairs teams for multiple business units within 3M – first for KCI Corporation, followed by Acelity Corporation, and then 3M Health Care Medical Solutions Division. Prior to that, he was chief of plastic surgery at the University of Maryland Medical Center and continues to hold academic appointments at both the University of Maryland and Johns Hopkins schools of medicine.
Dr. Silverman earned a Bachelor of Arts degree and a Doctor of Medicine degree from the University of Maryland and trained in surgery and plastic surgery with Harvard's Massachusetts General Hospital. He is certified by The American Board of Plastic Surgery, is on the advisory board for the University of Maryland Fischell Department of Bioengineering at the Clark School of Engineering and holds membership with 7 professional organizations. Dr. Silverman holds two patents, has authored more than 80 journal publications and contributed to several textbooks.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .
Contacts:
Media : Investors :
Troy Kirkpatrick Greg Rodetis
VP, Public Relations SVP, Treasurer & Head of Investor Relations
858.617.2361 551.255.1075
[email protected] [email protected]
SOURCE BD (Becton, Dickinson and Company)

21 %

Frequently Asked Questions

Who is the new CMO of BD?

Ronald Silverman, MD, has been appointed as the new CMO of BD.

When does Dr. Silverman start at BD?

Dr. Silverman will begin his role on December 4, 2023.

What will Dr. Silverman oversee at BD?

He will lead the Medical Affairs organization across BD's various units.

Who did Dr. Silverman replace at BD?

He replaces Dr. William Sigmund, who retired from BD.

What are Dr. Silverman's qualifications?

He holds a Doctor of Medicine degree and has extensive industry experience.

Last updated: Nov 21, 2023